Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuel Rodrigues

Showing results (21-30 of 199) with videos related to

Pageof 20
Sort By:
Bulletin Du Cancer|February 27, 2025
[Mirvetuximab soravtansine as monotherapy in platinum-resistant ovarian cancer expressing alpha folate receptor]Mathilde Reich, Manuel Rodrigues
Bulletin Du Cancer|March 16, 2024
[Dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer]Charles Raynaud, Manuel Rodrigues
Bulletin Du Cancer|June 7, 2022
[New drug approval: Pembrolizumab plus lenvatinib in second line for patients with advanced or recurrent endometrial cancer]Clara De Jesus, Manuel Rodrigues
Bulletin Du Cancer|November 10, 2022
[New drug approval: Tebentafusp for treatment of metastatic uveal melanoma HLA A*02:01-positive patients]Antoine Gaillard, Alexandre Matet, Manuel Rodrigues
Bulletin Du Cancer|February 26, 2021
[Pembrolizumab as first-line therapy in microsatellite instability metastatic colorectal cancers]Dimitri Pureur, Manuel Rodrigues, Anthony Turpin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2012
On the prevalence and causes of oncologist burnoutPierre Blanchard, Manuel Rodrigues, Philippe Colombat
Bulletin Du Cancer|November 10, 2022
[New drug arrival : Pembrolizumab as second-line treatment in MSI-H/dMMR endometrial, colorectal, gastric, intestinal and biliary cancers]Nathan El-Ghazzi, Benoit Rousseau, Manuel Rodrigues
Bulletin Du Cancer|February 10, 2018
[The place of cancer's cure in the personalized medicine and immunotherapy]Cecile Torregrosa, Manuel Rodrigues, Marie-France Mamzer-Bruneel
Acta Otorrinolaringologica Espanola|January 12, 2010
Lingual thyroid: an accidental findingMarta Neves, Paula Azevedo, Manuel Rodrigues e Rodrigues
Bulletin Du Cancer|August 21, 2025
[TRANSFORM-O: A new training program in translational research offered by the French Society of Cancer (SFC) and the French National College of Oncology Teachers (CNEC)]Stanislas Quesada, Camille Tlemsani, Christophe Massard, et al.
Pageof 20

Showing results (21-30 of 199) with videos related to

Sort By:
Pageof 20
Bulletin Du Cancer|February 27, 2025
[Mirvetuximab soravtansine as monotherapy in platinum-resistant ovarian cancer expressing alpha folate receptor]Mathilde Reich, Manuel Rodrigues
Bulletin Du Cancer|March 16, 2024
[Dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer]Charles Raynaud, Manuel Rodrigues
Bulletin Du Cancer|June 7, 2022
[New drug approval: Pembrolizumab plus lenvatinib in second line for patients with advanced or recurrent endometrial cancer]Clara De Jesus, Manuel Rodrigues
Bulletin Du Cancer|November 10, 2022
[New drug approval: Tebentafusp for treatment of metastatic uveal melanoma HLA A*02:01-positive patients]Antoine Gaillard, Alexandre Matet, Manuel Rodrigues
Bulletin Du Cancer|February 26, 2021
[Pembrolizumab as first-line therapy in microsatellite instability metastatic colorectal cancers]Dimitri Pureur, Manuel Rodrigues, Anthony Turpin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2012
On the prevalence and causes of oncologist burnoutPierre Blanchard, Manuel Rodrigues, Philippe Colombat
Bulletin Du Cancer|November 10, 2022
[New drug arrival : Pembrolizumab as second-line treatment in MSI-H/dMMR endometrial, colorectal, gastric, intestinal and biliary cancers]Nathan El-Ghazzi, Benoit Rousseau, Manuel Rodrigues
Bulletin Du Cancer|February 10, 2018
[The place of cancer's cure in the personalized medicine and immunotherapy]Cecile Torregrosa, Manuel Rodrigues, Marie-France Mamzer-Bruneel
Acta Otorrinolaringologica Espanola|January 12, 2010
Lingual thyroid: an accidental findingMarta Neves, Paula Azevedo, Manuel Rodrigues e Rodrigues
Bulletin Du Cancer|August 21, 2025
[TRANSFORM-O: A new training program in translational research offered by the French Society of Cancer (SFC) and the French National College of Oncology Teachers (CNEC)]Stanislas Quesada, Camille Tlemsani, Christophe Massard, et al.
Pageof 20